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stent (DES) placement.
Methods: All available material from our autopsy stent registry with duration of
implant >30 days to include a total of 384 cases (mean age¼6113 years, 287 male)
with 614 stented lesions in native coronary arteries (BMS¼266 [median, 832 days],
1st-gen DES¼285 [383 days], and 2nd-gen DES¼63 lesions [210 days]) were
pathologically evaluated for the involvement of neoatherosclerosis in stent thrombosis
and restenosis.
Results: The prevalence of VLST (>1 year) was greater in 1st-gen DES (19%) as
compared with BMS (3%) and 2nd-gen DES (0%), where in-stent plaque rupture from
neoatherosclerosis accounted for 83% of VLST in BMS (5 of 6) and 15% of VLST in
1st-gen DES (5 of 33). The involvement of neoatherosclerosis in VLST increased with
time; for duration of implants >3 years, all VLST in BMS (5 of 5) and 33% of VLST
in 1st-gen DES (4 of 12) were attributed to in-stent rupture. VLST from in-stent
rupture occurred earlier in 1st-gen DES (1434579 days) vs. BMS (2376545 days).
Of the 10 lesions with in-stent rupture, only 4 (BMS¼3, 1st-gen DES¼1) had in-stent
restenosis. In BMS, restenosis with underlying neoatherosclerosis was observed only
>3 years, and neoatherosclerosis accounted for 38% of BMS restenosis >3 years. In
contrast, both 1st- and 2nd-gen DES showed restenosis with neoatherosclerosis even
1 year. While only limited cases were available for 2nd-gen DES >1 year, 1st-gen
DES showed increased involvement of neoatherosclerosis in restenosis over time,
accounting for 31% of restenosis between 1 and 3 years and 78% of restenosis
>3 years.
Conclusions: Substantial involvement of neoatherosclerosis in late stent failure is
observed in both BMS and DES, which increases over time.
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Background: Noninferiority of biolimus-eluting stent (BES, Nobori) to everolimus-
eluting stent (EES, Xience) in clinical outcomes of drug-eluting stent (DES) im-
plantation has been reported; however, the difference in long-term clinical and
angiographic outcomes between them in the real world was little known. We aimed to
compare the two-year clinical and angiographic outcomes between EES and BES.
Methods: From 2010 to 2012, 4754 lesions received DES implantation: EES, 3391
lesions and BES, 1363 lesions. Midterm angiographic follow-up was scheduled at 8
months and late-term at 20 months. Target lesion revascularization (TLR) was deﬁned
as clinically or angiographically driven TLR. The TLR rate was calculated by the
Kaplan-Meier methods and compared by the long-rank test. Additionally, we analyzed
2978 lesions (EES, 1153 and BES 825) after late-term follow-up, which were free
from in-stent restenosis (ISR) and TLR at mid-term follow-up. ISR was deﬁned as
restenosis >50% and late catch-up phenomenon as the ﬁrst ISR over one year after
DES implantation.
Results: Between EES and BES, there were no signiﬁcant differences in the rates of
midterm restenosis (7.9% vs. 8.6%, p¼0.51), late catch-up phenomenon (5.8% vs.
4.4%, p¼0.13), and TLR (6.4% vs. 7.0%, log-rank p¼0.47). Meanwhile, in a sub-
group analysis, BES was signiﬁcantly more effective than EES to prevent late catch-
up phenomenon in lesion length 30 mm and ostial lesion in the right coronary artery
(see ﬁgure).Conclusions: The treatment effect on late catch-up phenomenon compared between
BES and EES implantations could depend on speciﬁc lesion characteristics.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/CoTCT-657
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Background: One of the hypothesized long-term clinical beneﬁts of Absorb BVS
(Abbott Vascular, Santa Clara, CA) is plaque regression and stabilization (reduction in
necrotic and lipid composition). This could also potentially mitigate in-stent
neoatherosclerosis, a late adverse effect that may be responsible for recurrent acute
coronary episodes. We present interim 1-year imaging evaluation (from an ongoing
4-year longitudinal study) of neointimal characteristics after coronary placement of
Absorb BVS in an atherosclerotic familial hypercholesterolemic (FH) swine model.
Methods: After 1 week of hypercholesterolemic diet, coronary arteries were balloon-
injured. After next 20 weeks on diet, injured segments were implanted with BVS (n¼
23) and everolimus-eluting metallic stents (EES, n¼11). Interim angiography, IVUS
and OCT were performed again at 1 year. OCT analysis included previously published
qualitative neointimal tissue assessment according to its pattern of backscatter and
optical intensity (homogeneous, heterogeneous or layered).
Results: At 1-year, all the scaffolds/stents were well apposed, widely patent and fully
covered with neointima. The scaffold thickness remained unchanged from baseline. The
percentage of OCT cross-sections with homogeneous pattern (previously linked to more
ﬁbrotic and less inﬂammatory histopathologic appearance) was signiﬁcantly higher in
BVS than EES (60% vs. 38%, p< 0.05). Also, the incidence of calcium around struts
trended lower for BVS (13.0%vs. 36.4%p¼0.11). Plaque tissue characterization (iMAP-
IVUS, Boston Scientiﬁc) showed lower absolute (0.200.17 mm2) and relative (63%)
lipid component area inBVSvs.EES(0.350.24mm2and83%, respectively, p<0.05).
Conclusions: One year after implantation in the familial hypercholesterolemic (FH)
swine model, the appearance of neointima by endovascular imaging suggests a more
stable and mature composition in BVS than in the EES, yet with less calciﬁcation.
This ongoing study is hoped to provide serial annual insights out to 4 years into the
long-term arterial response to BVS and EES in experimental atherosclerotic setting.
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Background: The mechanism and patterns of in-stent restenosis (ISR) comparing
bare metal stents (BMS) and 1st and 2nd generation drug-eluting stent (DES) as
evaluated by intravascular ultrasound (IVUS) have not been well delineated.
Methods: IVUS evaluation of in-stent restenosis (ISR) included core-lab based
assessments of morphology including ISR pattern (focal [< 10 mm] vs diffuse
[10 mm]), and/or any associated mechanical complication.
Results: There were 298 ISR lesions including 52 BMS, 73 sirolimus-eluting stents
(SES), 52 paclitaxel-eluting stents (PES), 16 zotarolimus-eluting stents (ZES), and
105 everolimus-eluting stent (EES) (Table). Mean pt age was 66.71.1 yrs, 74% were
male, 48.7% had diabetes mellitus, and 48.7% presented with acute coronary syn-
drome. BMS restenosis presented later (5.85.6 yrs) with more intimal hyperplasia.
Although reference lumen areas were similar among BMS and 1st and 2nd generation
DES, restenotic DES were longer and more often underexpanded with associated stent
fracture that was not seen in restenotic BMS.ronary Lesions - In-stent Restenosis B191
2nd
generation
DES
1st
generation
DES BMS p-value
Diabetes mellitus 57(53.3%) 68(48.9%) 19(36.5%) 0.14
ACS presentation 56(52.8%) 81(58.3%) 28(53.9%) 0.67
Duration from stent
implantation (yrs)
1.10.8 3.32.1 5.85.6 <0.001
Total stent length (mm) 32.218.7 29.416.1 21.813.5 0.001
Average reference lumen
area (mm2)
6.41.9 6.31.8 6.32.3 0.99
Minimum lumen area
(MLA) (mm2)
2.60.7 2.50.8 2.70.7 0.25
Minimum stent area (MSA) 4.71.6 4.91.6 6.42.2 <0.001
MSA <5mm2 69.2% 56.8% 28.8% <0.001
%NIH at MLA site 52.316.9 56.116.0 60.912.8 0.006
Diffuse ISR 28.0% 30.2% 28.8% 0.01
Stent fracture, n (%) 8.3% 5.8% 0.0% 0.10
Stent malapposition, n (%) 10.3% 10.1% 7.7% 0.86
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comConclusions: Although the mechanisms of restenosis seem to be similar between 1st
and 2nd generation DES, restenotic DES were characterized by more co-existent
mechanical complications (underexpansion and strut fracture) and less neointimal
hyperplasia than restenotic BMS.
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Background: Additional placement of limus stents (Sirolimus-eluting stent [SES] or
Everolimus-eluting stents [EES]) for the treatment of in-stent restenosis of SES (SES-
ISR) has been a matter of controversy. This prompted us to assess the clinical out-
comes of additional limus-stent in patients presenting with SES-ISR comparing with
balloon angioplasty (BA).
Methods: Enrollment included patients with SES-ISR undergoing repeat target lesion
revascularization (TLR). The patients were grouped according to treatment into EES,
SES and BA groups. The end points were a comparison of major adverse cardiac
events (MACE) composed by all-cause mortality, myocardial infarction and TLR, as
well as incidence of deﬁnite stent thrombosis (ST).
Results: Overall, 310 patients with SES-ISR were treated with [EES (n¼43), SES
(n¼102) and BA (n¼165)]. The baseline characteristics were similar among the
3 groups. The incidence of 1-year MACE was similar among the 3 groups (14.6%,
18%, 20%; respectively; p¼0.72). The incidence of ST was 0% in all the groups.
When the restenotic lesions were classiﬁed into the ﬁrst ISR versus recurrent ISR,
MACE-free rate for recurrent ISR was signiﬁcantly lower when compared with the
ﬁrst ISR for the entire cohort. (67.4% vs 83.8%; p¼0.006) (Figure). This was also
observed in the limus-stent treatment group (66.7% vs 85.5%; p¼0.029).Conclusions: The outcome of patients treated for SES-ISR is similar among ﬁrst- or
second-generation DES and BA. Patients with recurrent ISR are doing poorly even
with second-generation limus-stent.B192 JACC Vol 64/11/Suppl B j SeptembeTCT-660
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Background: Little is known about the effect of sirolimus-eluting stent (SES) im-
plantation in in-stent restenosis (ISR) lesion more than ﬁve years. We aimed to
compare the clinical outcomes up to nine years after the ﬁrst SES implantation be-
tween in ISR lesion and in de novo lesion.
Methods: A total of 395 patients underwent the ﬁrst SES implantation between
November 2002 and December 2004. There were 139 patients for ISR lesion and 256
patients for de novo lesion. We evaluated stent thrombosis (ST) and target lesion
revascularization (TLR) from the SES implantation to ﬁve years and beyond ﬁve
years. ST was deﬁned deﬁnite ST according to the Academic Research Consortium
deﬁnition.
Results: Complete nine-year follow-up was achieved in 91.9% (363/395). The cumu-
lative incidences of nine-year ST were 5.6% in the ISR group and 2.3% in the de novo
group (p¼0.17): TLR, 45.6% and 20.2% (p< 0.001) respectively. As the ﬁgure shows,
the TLR rate in ISR group was signiﬁcantly higher than in de novo group through nine
years, and the difference of the TLR rate in two groups increased in this period.Conclusions: The incidence of TLR after the SES implantation in ISR lesion was
signiﬁcantly higher than that in de novo lesion and the difference of the TLR rate
between in two lesions became more clear through nine years, although the incidence
of ST had no signiﬁcant difference in two lesions.
TCT-661
Vascular Brachytherapy versus Drug-Eluting Stents in the Treatment of In-Stent
Restenosis: a Meta-Analysis of Long Term Outcomes
Rhanderson N. Cardoso1, Alexandre M. Benjo2, Tyrone Collins2, Daniel Garcia1,
Francisco Y. Macedo3, Georges EL-Hayek4, Carlos Zamora5, Emad Aziz4,
James S. Jenkins2
1University of Miami Miller School of Medicine, Miami, FL, 2Ochsner Medical
Center, New Orleans, LA, 3Baylor College of Medicine, Houston, TX, 4St Luke’s
Rosevelt Hospital Center, New York, NY, 5Mount Sinai Medical Center, Miami, FL
Background: Clinical trials have shown a short term beneﬁt of drug eluting stents
(DES) compared to vascular brachytherapy (VBT) for the treatment of in-stent
restenosis (ISR). The long term beneﬁts of DES vs. VBT are conﬂicting in the
literature. This study aimed to do a meta-analysis of long term outcomes of DES
compared to VBT for treatment of ISR.
Methods: PubMed, EMBASE, Cochrane Central and unpublished data were searched
for cohort studies and randomized controlled trials (RCTs) that directly compared
VBT to DES for the treatment of ISR. We evaluated outcomes at 2 to 5 years of follow
up. Random-effects model was used for calculation of odds ratio (OR).
Results:We included 1,364 patients from 5 studies, of which 3 were RCTs. VBT was
used to treat ISR in 677 (49.6%) patients. After a 2 to 5 year follow up, no signiﬁcant
difference was found between treatment groups regarding myocardial infarction
(p¼0.50), stent thrombosis (p¼0.88), cardiovascular mortality (p¼0.35) and overall
mortality (p¼0.72). Target lesion revascularization (TLR; OR 2.39; CI 1.56-3.68;
p< 0.001) and target vessel revascularization (TVR; OR 2.27; CI 1.02-5.21; p¼0.04)
were signiﬁcantly increased in patients who received VBT. As illustrated in ﬁgure 1,
subanalysis including only RCTs showed consistent long-term beneﬁt of DES over
VBT for TLR (p¼0.01) and TVR (p¼0.04).r 13–17, 2014 j TCT Abstracts/Coronary Lesions - In-stent Restenosis
